Putting it All Together in Bipolar Disorder: Novel Treatment Options Focused on the Whole Patient

Thursday, April 13, 2023

2:15 PM – 3:15 PM USA

Presenter(s)

Rakesh Jain, MD

Clinical Professor
Texas Tech - Permian Basin
Texas Tech University School of Medicine - Permian Basin, Midland, Texas
Austin, Texas
CC

Craig Chepke, MD, DFAPA

Medical Director, Excel Psychiatric Associates; Adjunct Associate Professor of Psychiatry, Atrium Health
Excel Psychiatric Associates
Huntersville, North Carolina
Deborah Rosales-Elkins, MS, BS

Peer Support Specialist
Dell Medical School
Manor, Texas

Disclosure(s):

Deborah Rosales-Elkins, MS, BS: No financial relationships to disclose

The burden among adults living with bipolar ll disorder (BD2) is significant and effective identification and management remains a clinical challenge. A handful of therapies with novel mechanisms of action are emerging to better address the varied symptoms of BD2. In this session, expert faculty will explain ways to differentiate between BD2 and MDD; assess the impact of cardiometabolic burden on treatment adherence; update knowledge regarding the mechanisms of action, clinical indications, and pharmacotherapeutic characteristics of novel and emerging agents; as well as outline strategies to integrate these agents into patient-centered treatment. Join our faculty in a live Q&A session immediately following their presentation where they will answer the most popular questions asked during this session. Supported by an educational grant from Intra-Cellular Therapies, Inc.

Learning Objectives:

Describe the diagnostic challenges associated with BD, including differentiating between symptom domains as well as between BD1, BD2, and MDD
Assess the impact of cardiometabolic burden on treatment adherence and overall outcomes in patients with BD
Discuss the limitations of traditional antipsychotic agents and off-label therapies in BD and the latest clinical evidence/MOAs associated with newer/novel therapies
Evaluate the potential of newer/novel therapies to mitigate cardiometabolic AEs in patients with BD